La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

UCB Bilan de santé

Santé financière contrôle des critères 4/6

UCB possède un total de capitaux propres de €9.0B et une dette totale de €2.8B, ce qui porte son ratio d'endettement à 31.8%. Son actif total et son passif total sont €15.6B et de €6.7B. L'EBIT de UCB est €491.0M ce qui fait que son ratio de couverture des intérêts 3.8. Elle dispose de liquidités et de placements à court terme de €428.0M.

Informations clés

31.8%

Ratio d'endettement

€2.85b

Dette

Ratio de couverture des intérêts	3.8x
Argent liquide	€428.00m
Fonds propres	€8.95b
Total du passif	€6.68b
Total des actifs	€15.63b

Mises à jour récentes de la santé financière

Recent updates

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

Is UCB (EBR:UCB) A Risky Investment?

Mar 27

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Mar 04

UCB SA's (EBR:UCB) P/E Is On The Mark

Dec 28

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

Nov 12

Is UCB (EBR:UCB) Using Too Much Debt?

Aug 07

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Jun 02

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 05

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Apr 03

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 05

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 05

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Jun 06

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Apr 23

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Apr 09

UCB (EBR:UCB) Has Announced That It Will Be Increasing Its Dividend To €0.91

Mar 26

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Dec 23

Are Investors Undervaluing UCB SA (EBR:UCB) By 42%?

Dec 05

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

Sep 23

UCB SA (EBR:UCB) Shares Could Be 44% Below Their Intrinsic Value Estimate

Sep 05

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de UCB ( €3.3B ) dépassent ses passifs à court terme ( €2.8B ).

Passif à long terme: Les actifs à court terme de UCB ( €3.3B ) ne couvrent pas ses passifs à long terme ( €3.9B ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de UCB ( 27% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de UCB est passé de 19.7% à 31.8% au cours des 5 dernières années.

Couverture de la dette: La dette de UCB est bien couverte par le flux de trésorerie opérationnel ( 31.2% ).

Couverture des intérêts: Les paiements d'intérêts de UCB sur sa dette sont bien couverts par l'EBIT ( 3.8 x couverture).

UCB Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

Is UCB (EBR:UCB) A Risky Investment?

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

Is UCB (EBR:UCB) Using Too Much Debt?

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Recent updates

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB (EBR:UCB) Is Paying Out A Larger Dividend Than Last Year

Upcoming dividend of €0.91 per share

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome